Oruka Therapeutics financials
$82.15−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$122.1M |
| Net income | -$84.3M |
| Net margin | — |
| Diluted EPS | $-1.85 |
| EBITDA | -$122.0M |
| Operating cash flow | -$88.2M |
| Free cash flow | -$88.4M |
| Diluted shares | 45.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $46.9M | $61.6M |
| Short-term investments | $290.1M | $314.1M |
| Total debt | $0.00 | $0.00 |
| Total assets | $488.6M | $396.0M |
| Total liabilities | $16.7M | $13.8M |
| Shareholders' equity | $471.9M | $382.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology